Open AccessExamining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer
Author(s) -
Shun Lü,
Yan Yu,
Gisoo Barnes,
Xiusong Qiu,
Yuanyuan Bao,
Boxiong Tang
Publication year - 2022
Publication title -
the cancer journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.825
H-Index - 89
eISSN - 1540-336X
pISSN - 1528-9117
DOI - 10.1097/ppo.0000000000000583
Subject(s) - pemetrexed , medicine , lung cancer , quality of life (healthcare) , chemotherapy , oncology , performance status , randomized controlled trial , nursing , cisplatin
This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as first-line treatment on health-related quality of life (HRQoL) in patients with advanced nonsquamous non-small cell lung cancer (nSQ-NSCLC).